Back to results

Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD

Primary Purpose

Eosinophilic Esophagitis, Connective Tissue Disorders

Status

Completed

Phase

Phase 2

Locations

United States

Study Type

Interventional

Intervention

Losartan Potassium

About this trial

This is an interventional treatment trial for Eosinophilic Esophagitis focused on measuring Eosinophilic Esophagitis, Connective Tissue Disorders, Drug trial

Eligibility Criteria

5 Years - 21 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Confirmed diagnosis of eosinophilic esophagitis.
Have been on a high dose proton pump inhibitor for at least 8 weeks prior to a diagnostic endoscopy of eosinophilic esophagitis without histologic resolution.
Agree to maintain the same diet throughout the duration of the study.
If participant is female: meet one of the following criteria:
1. Is of non-childbearing potential (pre-menarchal or surgically sterile with documentation)
2. Is of childbearing potential with a negative urine pregnancy test at screening.

Exclusion Criteria:

Past or planned cardiac surgeries.
Had an aortic root Z-score greater than 3 on a previous echocardiogram.
Have intolerance to the study agent such as angioedema, IgE-mediated allergy.
Have renal dysfunction with creatinine in excess of the upper normal limit for age.
Have another disorder that causes esophageal eosinophilia (e.g., hypereosinophilic syndrome, Churg Strauss vasculitis, eosinophilic granuloma, or a parasitic infection).
Diagnosed with hepatic insufficiency.
History of abnormal gastric or duodenal biopsy or documented gastrointestinal (GI) disorders (e.g., Celiac Disease, Crohn's disease or helicobacter pylori infection.), not including chronic gastritis, chronic duodenitis, mucosal eosinophilia or other eosinophilic gastrointestinal disorders.
Used anti-immunoglobulin E [IgE] mAb, anti-tumor necrosis factor [TNF] mAb, anti-IL-5 agents, or anti-IL-13 within the last six months.
Used methotrexate, cyclosporine, interferon-α, or other systemic immunosuppressive or immunomodulating agents within the last three months.
Have a history of a stricture during an endoscopy procedure that prevents passage of the endoscope.
Taking or plan to take an angiotensin II receptor blocker (ARB) therapy, angiotensin-converting enzyme inhibitor (ACEI), beta blocker therapy (BB), or calcium channel blocker at the screening visit or at any time during the study, or have you been taking any of these medications for the last three months.
If the participant is female: pregnant or nursing.
Taking any investigative drug or device study within the last 30 days.
Had participated in any investigative biologics study within the last three months prior to the study entry.
Taking or plan to take hydrochlorothiazide, warfarin, cimetidine, phenobarbital, rifampin, or fluconazole.
If the participant is female: using a medically accepted effective method of birth control.
Will be able to complete all study procedures including endoscopy.
Taking or plan to take potassium supplements or salt substitutes containing potassium.

Sites / Locations

Kara Kliewer

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Losartan

Arm Description

Participants with eosinophilic esophagitis receive Losartan daily

Outcomes

Primary Outcome Measures

Percent of Participants in Histologic Remission at 16 Weeks

Percent of participants with peak eosinophil count < 15 eosinophils/high power field (remission) in distal and proximal esophagus

Secondary Outcome Measures

Change in Peak Eosinophil Count at 16 Weeks

Mean change in peak eosinophil count from baseline

Change in Pediatric EoE Symptom Score at 16 Weeks

The PEESS V2.0 questionnaire captures EoE-specific symptoms (dysphagia, GERD, nausea/vomiting, and pain) as reported by parents. The range for PEESS v2.0 scores is 0 to 100, with a higher score being indicative of more frequent and/or severe symptoms. Scores were obtained at baseline and 16 weeks. Change in score is defined as total score at 16 weeks minus total score at baseline.

Full Information

NCT ID

NCT01808196

First Posted

January 30, 2013

Last Updated

September 23, 2020

Sponsor

Children's Hospital Medical Center, Cincinnati

1. Study Identification

Unique Protocol Identification Number

NCT01808196

Brief Title

Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD

Official Title

A Preliminary, Open-label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue Disorder.

Study Type

Interventional

2. Study Status

Record Verification Date

August 2020

Overall Recruitment Status

Completed

Study Start Date

October 10, 2013 (Actual)

Primary Completion Date

January 13, 2015 (Actual)

Study Completion Date

February 13, 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Children's Hospital Medical Center, Cincinnati

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

The purpose of this research study is to test the safety of losartan potassium and see what effects (good and bad) it has on you and your eosinophilic esophagitis.

Detailed Description

Losartan is a drug that is approved by the United States Food and Drug Administration (FDA) for use in adults and children over 6 years of age who have high blood pressure. Losartan has been safe when administered to patients with normal blood pressure. This medication has not been studied in people with eosinophilic esophagitis or connective tissue disorder. Eosinophils are a type of white blood cell that induces inflammation. Eosinophils with other inflammatory cells produce a protein called TGF-β, which may contribute to part of EoE. Losartan may reduce the amount of this protein and therefore, be a treatment for eosinophilic esophagitis. You will be in the research study for approximately 4 months. Participation in this research study will involve 9 study visits. Of the 9 study visits, at least 3 visits will take place in the clinic; the other visits may take place over the telephone. Throughout the study, the following activities will occur: A physical and vital signs will be obtained There will be two endoscopies performed one at the beginning and one at the end of the study Blood will be obtained up to three times Pregnancy tests will be performed Quality-of-life questionnaires will be completed This is an open-label trial, which means that if you choose to enroll and you meet screening criteria, you will receive Losartan as a treatment. You will start the study drug at a low dose. It will be increased at vist 3 the 1 month visit. The dose of study drug will be increased depending on your weight and how well you tolerate each dose but will not exceed 100mg of study drug per day. It may be increased or decreased during the study if there are any side effects. If you do not have certain side effects, you will take each dose of the study drug between 21 and 28 days until your next study visit. You will swallow a pill or liquid once or twice a day. This study will consist of 4 phases: screening, treatment (titration and maintenance), end of treatment, and follow-up. Participants that are between 5 to 18 years of age, as well as the parent or legal guardian will be asked to complete questionnaires of quality-of-life symptom severity questionnaires. Participants between the age of 19 and 21 will also have to fill out these questionnaires, but parents/guardians will not have to fill these out. If you are the parent or caretaker, the only study activity in which you will be involved is the completion of questionnaires about you and your family.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Eosinophilic Esophagitis, Connective Tissue Disorders

Keywords

Eosinophilic Esophagitis, Connective Tissue Disorders, Drug trial

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 2

Interventional Study Model

Single Group Assignment

Model Description

This study is an open-label study which means that all participants receive the study medicine

Masking

None (Open Label)

Allocation

N/A

Enrollment

6 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Losartan

Arm Type

Experimental

Arm Description

Participants with eosinophilic esophagitis receive Losartan daily

Intervention Type

Drug

Intervention Name(s)

Losartan Potassium

Other Intervention Name(s)

Angiotensin II Receptor Antagonists

Intervention Description

The dose of study drug is dependent on body weight and tolerance but did not exceed 100 mg.

Primary Outcome Measure Information:

Title

Percent of Participants in Histologic Remission at 16 Weeks

Description

Percent of participants with peak eosinophil count < 15 eosinophils/high power field (remission) in distal and proximal esophagus

Time Frame

16 weeks after treatment

Secondary Outcome Measure Information:

Title

Change in Peak Eosinophil Count at 16 Weeks

Description

Mean change in peak eosinophil count from baseline

Time Frame

Baseline, 16 weeks after treatment

Title

Change in Pediatric EoE Symptom Score at 16 Weeks

Description

Time Frame

Baseline, 16 weeks after treatment

10. Eligibility

Sex

All

Minimum Age & Unit of Time

5 Years

Maximum Age & Unit of Time

21 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Confirmed diagnosis of eosinophilic esophagitis. Have been on a high dose proton pump inhibitor for at least 8 weeks prior to a diagnostic endoscopy of eosinophilic esophagitis without histologic resolution. Agree to maintain the same diet throughout the duration of the study. If participant is female: meet one of the following criteria: Is of non-childbearing potential (pre-menarchal or surgically sterile with documentation) Is of childbearing potential with a negative urine pregnancy test at screening. Exclusion Criteria: Past or planned cardiac surgeries. Had an aortic root Z-score greater than 3 on a previous echocardiogram. Have intolerance to the study agent such as angioedema, IgE-mediated allergy. Have renal dysfunction with creatinine in excess of the upper normal limit for age. Have another disorder that causes esophageal eosinophilia (e.g., hypereosinophilic syndrome, Churg Strauss vasculitis, eosinophilic granuloma, or a parasitic infection). Diagnosed with hepatic insufficiency. History of abnormal gastric or duodenal biopsy or documented gastrointestinal (GI) disorders (e.g., Celiac Disease, Crohn's disease or helicobacter pylori infection.), not including chronic gastritis, chronic duodenitis, mucosal eosinophilia or other eosinophilic gastrointestinal disorders. Used anti-immunoglobulin E [IgE] mAb, anti-tumor necrosis factor [TNF] mAb, anti-IL-5 agents, or anti-IL-13 within the last six months. Used methotrexate, cyclosporine, interferon-α, or other systemic immunosuppressive or immunomodulating agents within the last three months. Have a history of a stricture during an endoscopy procedure that prevents passage of the endoscope. Taking or plan to take an angiotensin II receptor blocker (ARB) therapy, angiotensin-converting enzyme inhibitor (ACEI), beta blocker therapy (BB), or calcium channel blocker at the screening visit or at any time during the study, or have you been taking any of these medications for the last three months. If the participant is female: pregnant or nursing. Taking any investigative drug or device study within the last 30 days. Had participated in any investigative biologics study within the last three months prior to the study entry. Taking or plan to take hydrochlorothiazide, warfarin, cimetidine, phenobarbital, rifampin, or fluconazole. If the participant is female: using a medically accepted effective method of birth control. Will be able to complete all study procedures including endoscopy. Taking or plan to take potassium supplements or salt substitutes containing potassium.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

J. Pablo Abonia, M.D.

Organizational Affiliation

Children's Hospital Medical Center, Cincinnati

Official's Role

Principal Investigator

First Name & Middle Initial & Last Name & Degree

Marc E Rothenberg, M.D., Ph.D.

Organizational Affiliation

Children's Hospital Medical Center, Cincinnati

Official's Role

Study Director

Facility Information:

Facility Name

Kara Kliewer

City

Mason

State/Province

Ohio

ZIP/Postal Code

45040

Country

United States

12. IPD Sharing Statement

Learn more about this trial

Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD

We'll reach out to this number within 24 hrs